- Home
- MNPR vs ZVRA Comparison
MNPR vs ZVRA Comparison
Compare MNPR & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | ZVRA |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.0M | 478.0M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MNPR | ZVRA |
|---|---|---|
| Price | $69.22 | $9.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $101.42 | $21.71 |
| AVG Volume (30 Days) | 325.4K | ★ 938.3K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $84,388,000.00 |
| Revenue This Year | N/A | $333.25 |
| Revenue Next Year | N/A | $43.70 |
| P/E Ratio | ★ N/A | $17.06 |
| Revenue Growth | N/A | ★ 244.60 |
| 52 Week Low | $24.00 | $6.19 |
| 52 Week High | $105.00 | $13.16 |
Technical Indicators
Market Signals| Indicator | MNPR | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 57.22 |
| Support Level | $57.86 | $8.08 |
| Resistance Level | $66.65 | $9.24 |
| Average True Range (ATR) | 5.60 | 0.42 |
| MACD | 0.99 | 0.09 |
| Stochastic Oscillator | 82.22 | 84.48 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.